Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

Injectable hydrogel relieves osteoarthritis pain and repairs cartilage in preclinical tests

For millions of people living with osteoarthritis, daily life can involve a frustrating cycle of pain and stiffness. While current treatments like over-the-counter medications or steroid injections can temporarily dull the ache, they do not stop the joint from deteriorating. A Yale study published in the journal Bioactive Materials found that the medication lacosamide acts as a highly effective, dual-purpose treatment that relieves joint pain and reverses cartilage damage in osteoarthritis, especially when a specialized hydrogel delivers the drug directly into the joint.

Radiologic analysis of large vestibular schwannoma position on surgical outcomes

Large vestibular schwannomas (VS) often compress the brainstem and differ in their relation to the internal auditory canal (IAC); the significance of these radiographic features on postoperative outcomes remains unclear. This study quantifies the impact of brainstem compression (BSC) and position relative to the IAC on surgical outcomes in VS.

We retrospectively identified 116 patients with sporadic unilateral VS ≥ 3 centimeters (2017–2022). Neurofibromatosis 2 cases were excluded. BSC was quantified with MRI T1 post-contrast axial images as the perpendicular distance from the brainstem-cerebellum to the point of maximal compression. Anterior and posterior IAC extension were measured relative to a line bisecting the IAC from the porus to fundus. Outcomes included postoperative facial nerve (FN) function, extent of resection (EOR), and length of stay (LOS).

Greater anterior extension was associated with decreased EOR in univariate analysis (OR = 1.12, p = 0.03), but not after controlling for tumor size and age (OR = 1.09, p = 0.158). Greater BSC was associated with worse FN function at 2–3 weeks postoperatively on univariate (OR = 1.08, p = 0.036) and approached significance on multivariate analysis (OR = 1.07, p = 0.08). Posterior extension was associated with increased LOS in univariate (β = 217.57 min, p = 0.024), but not multivariate analysis. Neither anterior extension nor BSC were associated with LOS. Older age correlated with a lower rate of GTR and longer LOS in multivariate analysis (EOR: OR = 1.05, p = 0.003; LOS: β = 79.84 min, p = 0.026).

Battleship-trained AI learns to ask sharper questions, boosting win rate from 8% to 82%

In 2026, the hype for artificial intelligence agents is louder than ever before. These semi-autonomous programs can “think” and execute well-defined tasks in areas like customer service and software development, typically using language models (LMs). But fields like medical diagnosis and scientific discovery require them to inquire about a vast range of solutions in uncertain environments which LMs struggle with.

Researchers at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and Harvard University’s School of Engineering and Applied Sciences (SEAS) peered deeper into LMs to understand their main issues in high-stakes settings. Their test: Battleship, a classic guessing game that’s helped cognitive scientists study how humans seek information.

CSAIL and SEAS scholars added a twist by reframing the game around asking and answering natural language questions. In their “Collaborative Battleship” game, one participant is a “captain” who inquires about where hidden ships are, while their teammate plays the “spotter” by responding to those questions in real time.

AI-designed universal coronavirus vaccine passes first human trial

Because the method does not require a needle, it could offer an alternative for people who are uncomfortable with injections. Researchers also believe it may make large scale vaccination campaigns easier and faster, particularly in settings where traditional injections are more difficult to administer.

Before human testing began, animal studies showed the vaccine could generate strong immune responses against multiple coronaviruses.

Inflammation-Induced Tumorigenesis and Metastasis

Inflammation, especially chronic inflammation, plays a pivotal role in tumorigenesis and metastasis through various mechanisms and is now recognized as a hallmark of cancer and an attractive therapeutic target in cancer. In this review, we discuss recent advances in molecular mechanisms of how inflammation promotes tumorigenesis and metastasis and suppresses anti-tumor immunity in various types of solid tumors, including esophageal, gastric, colorectal, liver, and pancreatic cancer as well as hematopoietic malignancies.

Under pressure: peroxisomes in cancer therapy resistance

Therapy resistance is a major obstacle to durable clinical responses. While genetic alterations and signalling rewiring are primary drivers of resistance, metabolic adaptation, which is closely intertwined with these processes, enables tumour persistence under therapeutic pressure and directly contributes to resistance. Peroxisomes are metabolic organelles with a role in controlling lipid metabolism, together with redox signalling and homeostasis—processes that intersect with pathways governing cancer behaviour and therapy response. Indeed, peroxisomal functions are remodelled to support metabolic plasticity and redox buffering under therapeutic stress.

Antibody fragment prevents hemorrhages associated with new Alzheimer’s treatments

In 2025, the European Medicines Agency approved two antibodies for Alzheimer’s disease: lecanemab (LeqembiTM, from Biogen) and donanemab (Kisunla, from Eli Lilly and Co.), both based on immunotherapy (the use of molecules from the immune system to treat diseases). These antibodies, obtained in the laboratory, act against the Aβ peptide, a protein fragment that accumulates in the brains of patients with Alzheimer’s disease. Elimination of this protein by the immune system helps slow the characteristic cognitive decline of the disease.

These two antibodies are the first disease-modifying therapies for Alzheimer’s. They stop and, in some cases, even partially reverse this devastating condition. However, a frequent and characteristic side effect of these drugs is cerebral bleeding, detectable by magnetic resonance imaging. The brain does not have the molecules and cells that make up the systemic immune system, so the entry of antibodies into the brain is not desirable under healthy conditions, although it is necessary for these treatments to be effective.

The incidence of bleeding in clinical trials ranged from 10% to 27% of treated patients, with a particularly high incidence in individuals carrying a specific apolipoprotein allele: APOEε4. In Europe, these treatments can be administered only to people with one or no copy of the APOEε4 allele, a genetic variant associated with a higher risk of Alzheimer’s.

New AI tools could help eye doctors diagnose retinal disease faster

Non-invasive eye scans allow doctors a zoomed-in, three-dimensional look beneath the eye’s surface without causing discomfort or pain to the patient. Used routinely in clinics worldwide, the scans produce detailed views of individual layers of the eye’s interior to help diagnose conditions that threaten vision. But with that level of precision comes a flood of data—hundreds of images per scan that physicians have to review manually, a time-consuming process that is vulnerable to human error.

Now, researchers at Washington University School of Medicine in St. Louis, in collaboration with colleagues at the University of Washington in Seattle and Genentech, Inc., have developed an experimental artificial intelligence (AI) system that can speed the scan review process and help doctors spot subtle signs of eye disease sooner. The technology, called OCTCube-M, includes a family of three AI models that are designed to read and interpret 3D images of the eye’s retina as well as other types of eye scans.

In a new study, the researchers found that, compared with older models, the new AI system more accurately identified eight different retinal diseases, including age-related macular degeneration, a common disease that damages the retina and is the leading cause of blindness in people over 50. It also was more accurate in its predictions of how fast a severe form of this condition, called geographic atrophy, would progress.

Creatine may supercharge immune cells that are key to fighting cancer

Creatine, the organic acid that is popularly taken as a supplement by athletes and bodybuilders, supercharges a critical class of immune cells that activate and prepare the body’s key cancer-fighters, according to new UCLA research.

The study, conducted in mouse models and human cells and published in iScience, builds directly on earlier work from the same lab showing that creatine powers killer T cells in their battle against tumors. Now, the team has discovered that creatine also fuels dendritic cells, specialized immune cells that capture tumor fragments and direct killer T cells to attack.

Most approved cancer immunotherapies work by targeting killer T cells directly, yet only about 20%–40% of patients respond to them. Bolstering the dendritic cells that train and activate T cells could potentially offer a way to bring the benefits of immunotherapy to more patients.

/* */